Osteogenon tablets 830mg, No. 40

• Prevention and treatment of primary osteoporosis of various etiologies (premenopausal, menopausal, senile);

• prevention and treatment of secondary osteoporosis of various etiologies (caused by rheumatoid arthritis, liver and kidney diseases, hyperthyroidism, hyperparathyroidism, bone formation imperfecta, the use of corticosteroids, heparin, immobilization);

• correction of osteopenia and disorders of phosphorus-calcium metabolism (including during pregnancy and during breastfeeding);

• acceleration of bone fracture healing.

Inside. With osteoporosis - 2-4 tablets. 2 times a day. For other indications - 1Ц2 table. per day.

Film-coated tablets of light yellow color, oblong, biconvex.

1 tab.

ossein-hydroxyapatite compound 830 mg

Excipients: microcrystalline cellulose, colloidal silicon dioxide, magnesium stearate, potato starch.

• Severe renal failure;

• hemodialysis;

• severe hypercalciuria;

• childhood;

• hypersensitivity to the components of the drug.

pharmachologic effect

A drug that affects bone mineralization (regulator of calcium-phosphorus metabolism).

Osteogenon contains the components necessary for the synthesis of bone tissue and has a double effect on the metabolism of bone tissue: it stimulates osteoblasts and inhibits osteoclasts.

Calcium is contained in the preparation in the form of hydroxyapatite (in a 2: 1 ratio with phosphorus), which contributes to its more complete absorption from the gastrointestinal tract. Inhibits the production of parathyroid hormone and prevents hormone-mediated bone resorption. The delayed release of calcium from hydroxyapatite results in the absence of a peak in hypercalcemia.

Phosphorus, participating in the crystallization of hydroxyapatite, promotes the fixation of calcium in the bone and inhibits its excretion by the kidneys.

Ossein is an organic component of the drug containing local regulators of bone tissue remodeling (?-transforming growth factor, insulin-like growth factors I and II, osteocalcin, collagen type 1), which activate the process of bone formation and inhibit bone resorption.

?-transforming growth factor stimulates the activity of osteoblasts, increases their number, promotes collagen production, and also inhibits the formation of osteoclast precursors.

Insulin-like growth factors I and II stimulate collagen and osteocalcin synthesis.

Osteocalcin promotes bone crystallization by binding calcium.

Collagen type 1 provides bone matrix formation.

Side effect

In very rare cases, the following are possible: allergic reactions; with prolonged use - hypercalcemia, hypercalciuria.

Application during pregnancy and lactation

Osteogenon can be used during pregnancy and during breastfeeding if indicated after consulting a doctor.

Application for impaired renal function

The use of the drug is contraindicated in severe hypercalciuria.

special instructions

In patients predisposed to urolithiasis, it may be necessary to adjust the dosage regimen of the drug, depending on laboratory parameters.

In patients with impaired renal function, prolonged use of high doses of the drug should be avoided.

The preparation contains only trace amounts of sodium chloride; therefore, it is permissible to use Osteogenon in patients with arterial hypertension.

Overdose

Currently, no cases of an overdose of Osteogenon have been reported.

Drug interactions

Osteogenon slows down the absorption of iron preparations, bisphosphonates and antibiotics of the tetracycline group, therefore, when used simultaneously with these drugs, the time interval between taking them should be at least 4 hours.

With the simultaneous use of Osteogenon with vitamin D or thiazide diuretics, the doctor should assess the risk of developing hypercalcemia due to increased calcium resorption.